Tarsus Pharmaceuticals Profit Margin

Tarsus Pharmaceuticals (TARS) currently reports a profit margin of -7.67% as of June 2026. That compares with -31.13% in the prior-year period — up 75.4% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Tarsus Pharmaceuticals's profit margin history and peer comparisons.

Tarsus Pharmaceuticals's profit margin increased from -31.13% to -7.67% — a 75.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tarsus Pharmaceuticals's profit margin of -7.67% is lower than the Healthcare sector average of 21.34%. That is roughly 135.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Tarsus Pharmaceuticals's current -7.67% should be judged against Healthcare norms (sector average: 21.34%) and against TARS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -7.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Tarsus Pharmaceuticals, and consider following TARS for alerts when major investors trade the stock.